Canakinumab for atherosclerotic disease

MRC-ILA Heart investigators, Alexander M Rothman, Allison C Morton, David C Crossman

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	197-8
Number of pages	2
Journal	New England Journal of Medicine
Volume	378
Issue number	2
DOIs	https://doi.org/10.1056/NEJMc1714635
Publication status	Published - 11 Jan 2018

Keywords

Antibodies, Monoclonal
Atherosclerosis
Humans

Access to Document

10.1056/NEJMc1714635

Cite this

@article{2bf8d544b6194118a8f283b7f3e16391,

title = "Canakinumab for atherosclerotic disease",

keywords = "Antibodies, Monoclonal, Atherosclerosis, Humans",

author = "{MRC-ILA Heart investigators} and Rothman, {Alexander M} and Morton, {Allison C} and Crossman, {David C}",

year = "2018",

month = jan,

day = "11",

doi = "10.1056/NEJMc1714635",

language = "English",

volume = "378",

pages = "197--8",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "2",

}

TY - JOUR

T1 - Canakinumab for atherosclerotic disease

AU - MRC-ILA Heart investigators

AU - Rothman, Alexander M

AU - Morton, Allison C

AU - Crossman, David C

PY - 2018/1/11

Y1 - 2018/1/11

KW - Antibodies, Monoclonal

KW - Atherosclerosis

KW - Humans

U2 - 10.1056/NEJMc1714635

DO - 10.1056/NEJMc1714635

M3 - Article

C2 - 29322756

SN - 0028-4793

VL - 378

SP - 197

EP - 198

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 2

ER -